Demographic and clinical characteristics and medication history of patients with psoriatic arthritis by BSA.
| Characteristics | Total, N = 1567 | BSA ≤ 3%, N = 789 | BSA > 3%, N = 451 |
|---|---|---|---|
| Demographics | |||
| Age, yrs, mean (SD) | 53.8 (13.3) | 54.4 (13.2) | 52.2 (13.4)† |
| Sex, n (%) | |||
| Men | 732 (48), n = 1541 | 372 (48), n = 777 | 224 (51), n = 443 |
| Women | 809 (52), n = 1541 | 405 (52), n = 777 | 219 (49), n = 443 |
| White, n (%) | 1428 (91) | 722 (92) | 402 (89) |
| BMI, mg/kg2, mean (SD) | 31.6 (7.2) | 31.2 (7.0) | 32.0 (7.5)* |
| Obese, BMI ≥ 30 kg/m2, n (%) | 788 (53), n = 1480 | 380 (51) | 238 (55) |
| Disease characteristics | |||
| Disease duration, yrs, mean (SD) | 8.6 (8.9) | 8.7 (8.6) | 9.0 (9.4) |
| Dactylitis, n (%) | 228 (15) | 104 (13) | 74 (16) |
| Enthesitis, n (%) | 420 (27) | 196 (25) | 116 (25) |
| MDA, n (%)‡ | 417 (42), n = 989 | NA | NA |
| Modified MDA, n (%)‡ | NA | 188 (30), n = 630 | 77 (21)†, n = 359 |
| TJC68, median (IQR) | 1 (0–5) | 0 (0–4) | 2 (0–7)* |
| SJC66, median (IQR) | 0 (0–2) | 0 (0–2) | 1 (0–4)§ |
| DAS28-CRP, mean (SD) | 2.8 (1.0) | 2.7 (1.0) | 3.0 (1.1)§ |
| CDAI, mean (SD) | 11.9 (8.7) | 10.7 (7.6) | 13.8 (10.0)§ |
| CRP, mg/l, mean (SD) | 3.0 (7.2) | 4.5 (10.2) | 4.3 (10.2)* |
| HLA-B27–positive, n (%) | 58 (18), n = 329 | 32 (19), n = 168 | 19 (19), n = 102 |
| History of comorbidities, n (%)** | |||
| Cardiovascular disease | 934 (60) | 469 (59) | 276 (61) |
| Diabetes mellitus | 220 (14) | 97 (12) | 76 (17)* |
| Any cancer | 115 (7) | 52 (7) | 41 (9) |
| Serious infections | 77 (5) | 38 (5) | 23 (5) |
| PRO measures | |||
| HAQ, 0–3, mean (SD) | 0.62 (0.65) | 0.54 (0.61) | 0.75 (0.7)§ |
| HAQ-S, mean (SD) | 0.63 (0.65) | 0.56 (0.61) | 0.76 (0.71)§ |
| VAS pain, 0–100, mean (SD) | 37.6 (29.2) | 33.5 (27.8) | 43.9 (30.7)§ |
| VAS fatigue, 0–100, mean (SD) | 40.5 (29.3) | 37.8 (28.6) | 44.6 (30.0)§ |
| WPAI, mean (SD) | |||
| Work time missed, % | 4.2 (15.1) | 2.4 (10.3) | 6.0 (18.0)† |
| Impairment while working, % | 16.9 (21.7) | 14.1 (19.6) | 22.1 (24.6)§ |
| Overall work impairment, % | 18.8 (23.8) | 15.5 (21.2) | 24.1 (26.3)§ |
| Activity impairment, % | 20.8 (24.3) | 16.9 (21.5) | 28.0 (27.6)§ |
| Medication use at enrollment | |||
| Prior biologic, n (%) | 1020 (65) | 517 (66) | 298 (66) |
| No. prior biologics, mean (SD) | 0.9 (0.7) | 1 (0.7) | 0.9 (0.7) |
| Prior csDMARD, n (%) | 1167 (74) | 604 (77) | 332 (74) |
| Prior prednisone, n (%) | 215 (14) | 111 (14) | 52 (12) |
| Current biologic use, n (%) | |||
| None | 631 (40) | 317 (40) | 177 (39) |
| Biologic monotherapy | 453 (29) | 223 (28) | 142 (32) |
| Biologic + csDMARD | 483 (31) | 249 (32) | 132 (29) |
| Biologic + MTX | 388 (25) | 200 (25) | 105 (23) |
| Current prednisone use, n (%) | 132 (8) | 67 (8) | 30 (7) |
↵* p < 0.05, BSA > 3% vs ≤ 3%.
↵† p ≤ 0.005, BSA > 3% vs ≤ 3%.
↵‡ Patients with MDA met 5 of 7 criteria: TJC (0–68) ≤ 1, SJC (0–66) ≤ 1, BSA ≤ 3%, patient VAS pain ≤ 15, patient’s global activity VAS ≤ 20, HAQ score ≤ 0.5, and tender entheseal points ≤ 1; for modified MDA, BSA criterion was excluded and patients met 5 of remaining 6 criteria listed above.
↵§ p < 0.0001, BSA > 3% vs ≤ 3%.
↵** Any cancer excludes nonmelanoma skin cancer; serious infections were defined as those leading to hospitalization or to intravenous antibiotics. BSA: body surface area; BMI: body mass index; MDA: minimal disease activity; TJC68: tender joint count in 68 joints; IQR: interquartile range; SJC66: swollen joint count in 66 joints; DAS28: 28-joint Disease Activity Score; CRP: C-reactive protein; CDAI: Clinical Disease Activity Index; PRO: patient-reported outcomes; HAQ: Health Assessment Questionnaire; HAQ-S: HAQ for the Spondylarthropathies; VAS: visual analog scale; WPAI: Work Productivity and Activity Impairment questionnaire; csDMARD: conventional synthetic disease-modifying antirheumatic drug; MTX: methotrexate; NA: not applicable; n: no. patients with available data (given in cases where this number differs from the N number in the column heading).